Cognition Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Cognition TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 16.4% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 69.8% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-16.4%

Wachstumsrate der Gewinne

-3.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	24.3%
Wachstumsrate der Einnahmen	69.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

May 22

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Apr 18

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Nov 30

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Aug 15

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Mar 17

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

Sep 27

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Aug 12

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

Aug 05

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Mar 19

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:CGTX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-73	-71	N/A	5
12/31/2025	N/A	-51	-60	-31	6
12/31/2024	N/A	-37	-56	-24	6
3/31/2024	N/A	-29	-21	-21	N/A
12/31/2023	N/A	-26	-16	-16	N/A
9/30/2023	N/A	-23	-21	-21	N/A
6/30/2023	N/A	-23	-17	-17	N/A
3/31/2023	N/A	-24	-18	-18	N/A
12/31/2022	N/A	-21	-19	-19	N/A
9/30/2022	N/A	-24	-8	-8	N/A
6/30/2022	N/A	-22	-10	-10	N/A
3/31/2022	N/A	-19	-6	-6	N/A
12/31/2021	N/A	-16	-4	-4	N/A
9/30/2021	N/A	-12	-4	-4	N/A
6/30/2021	N/A	-10	-3	-3	N/A
3/31/2021	N/A	-9	-5	-5	N/A
12/31/2020	N/A	-12	-3	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CGTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CGTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CGTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CGTX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CGTX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CGTX in 3 Jahren voraussichtlich hoch sein wird

Cognition Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 19% to US$6.25

Price target decreased by 26% to US$7.75

Price target decreased by 8.7% to US$10.50

Price target decreased to US$11.50

Recent updates

Cognition Therapeutics, Inc. Announces Results from Cognition Therapeutics' Phase 2 Shine Study of CT1812 in Mild-To-Moderate Alzheimer's Disease Accepted for Presentation at AAIC

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

New major risk - Financial position

Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

Cognition Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Cognition Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Cognition Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $11.499999 million.

Cognition Therapeutics, Inc. Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-To-Mod Moderate Alzheimer's Disease

Cognition Therapeutics, Inc. Appoints Quang Pham as Board Director

Cognition Therapeutics, Inc. Appoints Quang Pham as Board Director

Cognition Therapeutics, Inc. Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease At CTAD

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 19% to US$6.25

Cognition Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Share price stability

Cognition Therapeutics, Inc. and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 Start Study in Early Alzheimer's Disease

Cognition Therapeutics, Inc. Announces Positive Topline Results for CT1812 Phase 2 Sequel Study for Mild-To-Moderate Alzheimer’s Disease

Cognition Therapeutics, Inc. Publishes Clinical Evidence that CT1812 Displaces Aß Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease

Price target decreased by 26% to US$7.75

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.7% to US$10.50

Cognition Therapeutics, Inc. Completes Enrollment of CT1812 Phase 2 Sequel Study for Mild-to-Moderate Alzheimer’s Disease

Cognition Therapeutics, Inc. Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease

Cognition Therapeutics, Inc Presents Scientific Rationale, Clinical Biomarker and Preclinical Data Supporting A Phase 2 Clinical Trial with Ct1812 in Geographic Atrophy Secondary to Dry AMD

Cognition Therapeutics, Inc. Highlights Phase 2 Shimmer Study of Ct1812 in Dementia with Lewy Bodies in Presentation At Ctad

Price target decreased to US$11.50

High number of new and inexperienced directors

Cognition Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support Sequel Clinical Trial

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Cognition Therapeutics, Inc. Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer's Disease Processes

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

Cognition Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Cognition Therapeutics, Inc. Announces CFO Changes

Cognition Therapeutics, Inc. Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

Cognition Therapeutics, Inc. to Report Q1, 2022 Results on May 11, 2022

High number of new and inexperienced directors

Cognition Therapeutics, Inc., Annual General Meeting, Jun 10, 2022

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

High number of new and inexperienced directors

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken